{"id":970473,"date":"2026-06-04T07:03:39","date_gmt":"2026-06-04T11:03:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/"},"modified":"2026-06-04T07:03:39","modified_gmt":"2026-06-04T11:03:39","slug":"lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/","title":{"rendered":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death"},"content":{"rendered":"

<\/p>\n

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death<\/b><\/p>\n

\u2014 New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress \u2014<\/b><\/p>\n

ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE<\/a>)–
\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS\u00ae<\/sup> in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation<\/a>). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard ratios (HRs) favored treatment with LUPKYNIS for the following individual components of the composite endpoint: death (HR=0.19 [an 81% reduction in risk]; p=0.0929), treatment failure (HR=0.45 [a 55% reduction in risk]; p=0.0062) and worsening proteinuria (HR=0.22 [a 78% reduction in risk]; p<0.0001).<\/p>\n

\n\u201cThis new time-to-event analysis demonstrates LUPKYNIS\u2019 favorable effect on clinically important outcomes in lupus nephritis patients,\u201d commented Amit Saxena, MD, Associate Professor of Medicine, NYU Grossman School of Medicine Division of Rheumatology and lead author of the EULAR presentation. \u201cLUPKYNIS is the only treatment that has demonstrated a statistically significant improvement in complete renal response (CRR) in as short as 6 months in a randomized Phase 3 clinical study. These new results further characterize the benefits that LUPKYNIS can bring to patients suffering from lupus nephritis.\u201d<\/p>\n

About Aurinia<\/b><\/p>\n

\nAurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260604275075\/en\/<\/a><\/span><\/p>\n

Investor Inquiries: ir@auriniapharma.com<\/a><\/b><\/p>\n

KEYWORDS:<\/b> United States North America Canada Maryland<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Clinical Trials Biotechnology Other Health Health Pharmaceutical General Health Other Science Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death \u2014 New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress \u2014 ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS\u00ae in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard … <\/p>\n

Continue reading “LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970473","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death \u2014 New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress \u2014 ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS\u00ae in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard … Continue reading "LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T11:03:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death\",\"datePublished\":\"2026-06-04T11:03:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/\"},\"wordCount\":356,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/\",\"name\":\"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-06-04T11:03:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/","og_locale":"en_US","og_type":"article","og_title":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk","og_description":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death \u2014 New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress \u2014 ROCKVILLE, Md. & EDMONTON, Alberta–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS\u00ae in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new analysis on the safety population of 356 patients (178 on LUPKYNIS and 178 on placebo) indicates that LUPKYNIS was associated with a statistically significant 53% reduction in the risk of renal-related event or death (hazard ratio=0.47; p=0.0007). Hazard … Continue reading \"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T11:03:39+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death","datePublished":"2026-06-04T11:03:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/"},"wordCount":356,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/","name":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-06-04T11:03:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260604275075r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lupkynis-associated-with-a-statistically-significant-53-reduction-in-risk-of-renal-related-event-or-death\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970473"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970473\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}